People and Business News — 9/22
The latest business and people happenings from the last month, all in one place.
People News
Clinovo appointed Nandish Poluru as Chief Executive.
Allucent, announced the appointment of Steffany Cox as its chief marketing officer.
Susan Robbins joined HeartcoR Solutions as its director of training. Additionally, Michelle Mills has joined the organization as director of ECG analysis and quality control.
MMS Holdings Inc. announced the appointment of Kelly J. Hill to Chief Strategy Officer.
Florence Healthcare has hired Kristin Surdam, who will lead the company’s thought leadership team and efforts to engage sponsors and contract research organizations, and Gunnar Esiason, who will lead patient-facing strategies.
Elligo Health Research announced Chief Scientific Officer Rebecca Kush, PhD, was recently elected Chair of the Vulcan Advisory Council.
Promontory Therapeutics Inc. announced the appointments of Helene Shea, PhD, as Vice President of Chemistry, Manufacturing and Controls, and Kate Hogg Call as Vice President of Clinical Operations.
Parexel promoted Peyton Howell to the newly created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.
Business News
Strata Oncology, Inc. announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH) trial.
Recognition
Jumo Health announced it has made Inc. Magazine’s Inc. 5000 list.
LaQuinta Jernigan, Chief Operating Officer for mdgroup, has been recognized as one of 100 most inspiring people in life sciences.
WCG’s Vice President, Patient Advocacy and Clinical Research Diversity, Lori Abrams, has been named a Diversity, Equity, and Inclusion Champion.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025